WO2022011439A1 - Implant sous-cutané réabsorbable de longue durée à libération prolongée de substance pharmacologiquement active pré-concentrée en polymère pour le traitement de l'obésité et procédé - Google Patents

Implant sous-cutané réabsorbable de longue durée à libération prolongée de substance pharmacologiquement active pré-concentrée en polymère pour le traitement de l'obésité et procédé Download PDF

Info

Publication number
WO2022011439A1
WO2022011439A1 PCT/BR2020/050348 BR2020050348W WO2022011439A1 WO 2022011439 A1 WO2022011439 A1 WO 2022011439A1 BR 2020050348 W BR2020050348 W BR 2020050348W WO 2022011439 A1 WO2022011439 A1 WO 2022011439A1
Authority
WO
WIPO (PCT)
Prior art keywords
implant
treatment
obesity
polymer
active substance
Prior art date
Application number
PCT/BR2020/050348
Other languages
English (en)
Portuguese (pt)
Inventor
Edson LUIZ PERACCHI
Original Assignee
Luiz Peracchi Edson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luiz Peracchi Edson filed Critical Luiz Peracchi Edson
Publication of WO2022011439A1 publication Critical patent/WO2022011439A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Definitions

  • the present application for the privilege of invention is aimed at the health sector and comprises a long-lasting resorbable subcutaneous implant with prolonged release of pre-concentrated pharmacologically active substance in polymer for the treatment of obesity.
  • Obesity is a chronic disease associated with several medical conditions and a high mortality rate. It is considered a multifactorial disease, since many factors influence weight control and eating habits, such as genetics, culture, behavioral and situational factors.
  • Obesity is characterized by an imbalance between caloric intake and expenditure, with a positive energy balance. This can be due to intake greater than expenditure, reduction in total caloric expenditure, or a combination of these two factors. It is possible that obesity is caused by other factors such as endocrine disorders, drugs or neurological disorders, but they constitute a very small fraction of cases. It is also characterized by an excessive accumulation of adipose tissue in the body, reflecting on the obese phenotype and compromising the individual's health.
  • BMI body mass index
  • the BMI is an index calculated from the weight divided by the square of the person's height (kg/m 2 ), the result obtained indicates in which category the individual fits in terms of body composition.
  • the existing categories are: underweight (BMI ⁇ 18 kg/m 2 ); normal (BMI between 18-25 kg/m 2 ), overweight (BMI between 25-30 kg/m 2 ) and obesity (BMI> 30 kg/m 2 ).
  • Obesity can be subdivided into degrees: I (BMI between 30 and 34.9 kg/m 2 ); II (BMI between 35 and 39.9 kg/m 2 ); III (BMI>40 kg/m 2 ).
  • there are other techniques to quantify obesity such as measuring waist circumference, measuring skinfolds, magnetic resonance imaging of the total amount of adipose tissue, among others.
  • Obesity is associated with the emergence of several comorbidities, such as diabetes mellitus, arterial hypertension, cardiovascular diseases, dyslipidemia, osteoporosis, gallbladder diseases and some types of cancer.
  • diabetes mellitus is associated with obesity, whereas type 2 diabetes mellitus is five times more prevalent in moderately obese people and ten times more prevalent in severely obese people.
  • Brazif' was carried out to project data on obesity, related diseases and costs associated with obesity in the health system in Brazil for the year 2050.
  • thirteen obesity-related diseases were considered: coronary artery disease, stroke, hypertension, type 2 diabetes, knee osteoarthritis, and eight types of cancer (breast; kidney; colorectal; esophageal; endometrial; pancreatic; liver; gallbladder).
  • three scenarios were proposed. hypothetical, without intervention in the progression of obesity; 1% reduction in the BMI of the obese population; 5% reduction in the BMI of the obese population.
  • the projection for 2050 is that type 2 diabetes, knee osteoarthritis and eight types of cancer will double compared to 2010. Coronary artery disease and stroke will almost double from 2010 to 2050. Also in this same period the projection for the increase in cases of hypertension is 62%.
  • a 5% reduction in the BMI of the obese population by 2050 would reduce the cases of obesity-related diseases, in relation to the total Brazilian population, by: 21,000 cases of the eight types of cancer; 600,000 cases of coronary artery disease and stroke; 2,500,000 cases of knee osteoarthritis; 2,100,000 cases of type 2 diabetes; 5,400,000 cases of hypertension.
  • Patients who should be evaluated regarding the use of medication in their treatment are those with a BMI equal to or greater than 30 kg/m 2 , categorized as obese, those with a BMI equal to or greater than 25 kg/m 2 and who have other factors risk factors such as hypertension, type 2 diabetes mellitus, hyperlipidemia, among others, and patients in whom conventional treatment with diet and exercise alone was not effective.
  • Drug therapy for the treatment and control of obesity has three mechanisms of action: acting on the central nervous system, altering appetite and eating habits, called appetite suppressants; increasing thermogenesis, called thermogenic agents; acting on the gastrointestinal system by inhibiting the absorption of fat, called digestion inhibitors.
  • Appetite suppressants also known as anorectics, are divided into two classes, noradrenergic and serotonergic, which act on the appetite center and satiety center, respectively.
  • noradrenergic anorectics are diethylpropion, phenproporex, phentermine, mazindol and phenylpropalamine.
  • Diethylpropion, fenproporex and phentermine are derivatives of amphetamine, originally used for weight loss. Due to the addictive potential of amphetamine its chemical structure was changed, through the manipulation of its side chains and rings, to the alternatives found on the market today. The drugs used today maintain the anorectic properties of amphetamine, but have a significant reduction in the stimulant effect and its additive potential.
  • Diethylpropion dosage of 40-120 mg/day, fenproporex, dosage of 20-50 mg/day and phentermine, dosage of 30-60 mg/day, act on the central nervous system by increasing the neurotransmission of catecholamine and stimulating its receptors, increasing the sympathetic activity, thereby reducing appetite and, consequently, food intake.
  • Phenylpropanolamine dosage of 50-75 mg/day, is a non-catecholamine sympathomimetic agent, which mimics the action of adrenaline and noradrenaline and acts as an appetite suppressant.
  • Serotonergic anorectics such as fenfluramine, dexfenfluramine, fluoxetine and sertraline, affect the satiety center.
  • Fenfluramine dosage of 60-120 mg/day and dexfenfluramine, dosage of 30 mg/day, act on the hypothalamus causing decreased food intake through partial inhibition of serotonin reuptake and serotonin release in the synaptic cleft.
  • Fluoxetine dosage of 20-60 mg/day and sertraline, dosage of 50-150 mg/day, selectively inhibit serotonin reuptake and despite not being regulated as drugs for obesity they promote weight loss. and can be useful in patients who have a condition of compulsion, bulimia nervosa and/or depression.
  • sibutramine which is a combination of noradrenergic and serotonergic anorectic and acts centrally and peripherally, inhibiting the uptake of both serotonin and noradrenaline, decreasing food intake and increasing caloric expenditure. Its dosage is 10-20 mg/day.
  • thermogenic drugs Another line of treatment for obesity is using thermogenic drugs.
  • One of them is the combination of ephedrine with caffeine and/or aminophylline, which has both thermogenic and anorexic properties.
  • Ephedrine dosage of 50-75 mg/day, increases the release of noradrenaline, decreasing food intake.
  • Caffeine and aminophylline dosage of 100-300 mg/day and 300-450 mg/day, respectively, increase the action of noradrenaline on nerve endings, potentiating and acting in synergy with ephedrine.
  • Orlistat dosage of 120 mg at most three times a day, is a drug that acts by inhibiting the lipase enzyme. This enzyme, present in the stomach and pancreas, breaks down the fat present in food. Orlistat inhibits the action of this enzyme, consequently inhibiting the digestion of triglycerides and decreasing the absorption of cholesterol and fat-soluble vitamins.
  • Other digestion-inhibiting drugs act by replacing fat in food, aiming to reduce fat intake, but maintain the flavor in the food consumed by patients.
  • These substitutes can be made from carbohydrates and improve the texture, thickness, stability and moisture of the food. They can be substitutes produced from proteins, which give the food the sensation of fat in palatability, but can increase the amount of calories. They can also be substitutes made from fats that are low in calories and add a creamy, fat-like texture to foods. These substitutes can increase patients' adherence to the diet.
  • Another article entitled “Comparison of continuous and intermittent anorectic therapy in obesity” analyzed the results of a 36-week double-blind study that evaluated the efficacy of continuous and intermittent treatment of the anorectic phentermine.
  • 108 women were selected who were overweight or obese at least 20% above the standard, aged between 21 and 60 years and without a history of cardiovascular and endocrine diseases. They were divided into three groups: one received a placebo; another received 30 mg/day of phentermine and the third received alternating doses of placebo or phentermine every four weeks.
  • Chronic diseases such as obesity, make the patient have to take at least one medication, often more than once a day, indefinitely to keep the disease under control.
  • the increase in the number of drugs ingested by the patient per day decreases adherence to treatment by about 20% and drugs used in multiple doses also decrease adherence compared to a single dose.
  • extended-release drugs can reduce the adverse side effects of treatment with anorectics, effects that may result from the high serum concentration of these drugs after oral intake.
  • implants or bioabsorbable anorectic pellets for the treatment of obesity.
  • Such implants present sustained drug release for a long period of time, avoiding concentration peaks and rapid decline of the drug in the body, in order to treat and control the disease and make the treatment independent of the patient taking medication, thus improving weight loss and maintenance.
  • implant or “pellet” refer to this pharmaceutical form already consolidated in the official collections of standards for drugs and pharmaceutical substances. They are characterized by being solid, sterile preparations of a suitable size and shape for parenteral implantation and delivery of the active substance(s) over an extended period of time.
  • extended release refers to the form of drug release through the implant, which occurs in a continuous and gradual manner over an extended period of time and does not result in a immediate and concentrated drug in the body.
  • Biodegradable polymers or bioerodible polymers refer to a polymer that degrades in vivo and that its erosion over time occurs. concomitantly with and/or subsequently the release of the therapeutic agent.
  • a biodegradable polymer can be a homopolymer, copolymer or a polymer compressing more than two polymer units. In some cases, a biodegradable polymer may include the blending of two or more homopolymers or copolymers.
  • Biodegradable implants or bioerodible implants can be understood as implants that have some mechanism that gradually reduces their mass over a prolonged period of release time.
  • the forces involved in this mass reduction can be cellular interaction or shear forces on the implant surface.
  • erosion and gradual dissolution of its components are possible.
  • the terms also refer to the total degradation and absorption by the body that occurs at the place where the implants were applied, excluding the need to remove the implants at the end of the treatment.
  • Contraceptive implant mentions an implant of polymeric material that can release a contraceptive agent for a relatively long time when adjusted subcutaneously or locally.
  • the implant comprises an ethylene/vinyl acetate copolymer core material that functions as a matrix for a contraceptive substance, an ethylene/vinyl acetate membrane surrounding the core material, and a contact layer at the interface of the core material and membrane that prevents the material from separating from the membrane core.
  • the second registration number US9980850 (Bioerodible contraceptive implant and methods of use ⁇ bGbo ⁇ describes a bioerodible contraceptive implant and methods of use in the form of a bioerodible controlled-release granule for subdermal implantation.
  • the bioerodible sediment provides the sustained release of a contraceptive agent over an extended period.
  • Bioerosion products are water soluble, bioresorbable or both, avoiding the need for surgical removal of the implant.
  • the present invention aims to be a tool, which combined with changes in the patients' lifestyle, promotes weight loss and maintenance of this loss through a resorbable implant. with anorectic agent.
  • the proposed treatment does not depend on the patient's memory and commitment to make the correct use of the medication and through the prolonged release of the active substance it is possible to reduce the adverse symptoms observed orally and avoid the hepatic metabolism of the drug, since it is released directly into the body. blood flow.
  • the implants' duration it is not necessary to remove them, only the reinsertion of new ones to maintain the treatment.
  • Figure 3 - Graph that relates a scale from 0 to 10 of factors monitored by the patient in the case study using implants bioabsorbables of diethylpropion as a function of time, for the first three weeks of treatment, in which 0 is the equivalent of “little” and 10 is the equivalent of “a lot”, whether for hunger, sleep quality, anxiety and disposition.
  • the present application for the privilege of invention is a biodegradable implant with an anorectic agent in a polymer matrix.
  • the implant is inserted subcutaneously and has a continuous release of the active for an extended period of time. This release aims to ensure an efficient, constant and prolonged serum level of the drug for the treatment of obesity.
  • active substance refers to an anorectic, which can be: diethylpropion, fenproporex, phentermine, mazindol, phenylpropalamine, fenfluramine, dexfenfluramine, fluoxetine and sertraline.
  • the implant of the present invention may have only the anorectic in its constitution, but it is preferably formed by particles of the anorexigen homogeneously dispersed in a bioerodible and bioabsorbable polymeric matrix.
  • This polymer matrix can be formed by a polymer or a mixture of polymers.
  • the amount of anorectic present in the implant can vary from 25 to 250 mg per implant and its composition has from 1 to 20% of biodegradable polymer in proportion to its weight.
  • the biodegradable polymer used can be: Poly(D-lactic acid),
  • PVP polyvinylpyrrolidone
  • PVA poly(vinyl alcohol)
  • PEO poly(ethylene oxide)
  • Implants can have any size, shape or structure that facilitates their manufacture and subcutaneous insertion, however, to obtain a more constant and uniform release of the active, it is necessary to use geometric shapes that maintain their surface area over time.
  • the implant developed and demonstrated in the The present order adopts the cylindrical pattern (1), in the shape of a rod, provided with straight or rounded ends, with a length between 2 and 25 mm and a diameter of 1 to 6 mm.
  • a schematic drawing of an example of implant dimension (1 ) is shown in figure 1.
  • the manufacture of the anorectic implant can be made from the addition of 25 to 250 mg of the drug in the chosen biodegradable polymer matrix solution in a proportion of 1 to 20% in relation to the weight of the drug, with the formation of a mixture homogeneous. If the polymer solvent is not also the anorectic solvent, it will be dispersed in the form of particles or suspension, and a mixer can be used to make the solution homogeneous. This solution is then dried and then molded to the shape of the implant (1) or other desired shape.
  • anorectic implant Another possible way of manufacturing the anorectic implant is from the mixture of 25 to 250 mg of the drug and 1 to 20% of the biodegradable polymer matrix chosen in relation to the weight of the drug, in its dry, powdered forms.
  • the drug and polymer matrix are added to a suitable container and the mixture is homogenized.
  • the mixture of actives for manufacturing the implant can be molded from pressure or heat, so as not to compromise the effectiveness of the drug or degrade the polymeric material.
  • the options for implant molding techniques can be: injection molding, hot molding, compression molding or extrusion molding.
  • the technique chosen was compression molding.
  • the mixture of actives, in powder form is added to a mold and mechanical force is applied under the mixture, generating the compression of the particles and, consequently, the molding of the implant in the format (1).
  • the filling and sterilization of the anorectic implant can be done by heat or gamma rays.
  • the implant may have a polymeric membrane coating, with a thickness between 0.1 to 0.7 mm.
  • the polymer used for the coating must be bioabsorbable and allow the passage of the active.
  • the implant coating is preferably done by immersing the implant in a polymeric solution.
  • the coating can cover the entire surface of the implant including the edges, only its longitudinal surface with the edges uncoated or coated only on the edges of the implant without coating its length.
  • the polymers that can be used for the coating are: poly(lactic acid-co-glycolic acid) (PLGA) and copolymers of D,L-lactic acid.
  • Non-biodegradable or non-bioerodible implants (2) (figure 2) have a central core (2.1) formed by polymeric matrix in the percentage of 1 to 20% in relation to the weight of the drug, in this case from 25 to 250 mg of anorectic, with the core surrounded by a non-degradable polymeric membrane (2.2) that controls the rate of drug release.
  • the material for manufacturing the polymeric membrane that surrounds the implant can be: silicone, urethane, acrylates and their copolymers, polyvinylidene fluoride copolymers, polyethylene vinyl acetate-ethylene vinyl acetate, dimethylpolysiloxane.
  • This membrane has a thickness of 0.2 to 1 mm and is molded using our own equipment. After molding the membrane from the polymeric material, the active mixture is inserted, forming the central core (2.1) of the implant (2).
  • the polymers used in the polymer matrix and the mixture adopt the same compounds and process as the bioabsorbable implant.
  • Drug release in this system occurs through diffusion at a relatively constant rate, and it is possible to change the rate of drug release through the thickness or material of this membrane. In this system, there is a need to remove the implant at the end of the treatment.
  • the treatment for obesity using anorectic implants should be defined according to the patient's clinical condition, taking into account that the duration of the implant is approximately 3 to 6 months, this time being the proposed period between implant insertions.
  • Treatment with anorectic implants has the advantage of needing about 8-20% of the doses used orally.
  • the dose reduction is due to the implantation of the drug in the subcutaneous layer, which prevents its first-pass metabolism, thus reducing the dose required to maintain active bioavailability.
  • the prolonged release of the active through the implant avoids sub- or supraphysiological plasma concentrations, the “peaks and valleys” that occur with oral administration.
  • anorectics such as dry mouth, nausea, sweating, sleep disturbance, irritability, headache, constipation, keeping the drug concentration within the therapeutic window found in the literature.
  • the maximum suggested dosage is 120 mg/day.
  • the patient would use 10.8 g.
  • the dosage could drop to about 0.9 g (8%) to 2.2 g (20%) in the same time interval, achieving a similar therapeutic effect in addition to all the aforementioned benefits.
  • the use of the implant proposed here is safe and effective in the treatment of obesity, given that the therapy does not depend on the patient's will or discipline for the action of the drug, thus ensuring the maintenance of the dosage and regularity of the treatment. .
  • the use of these implants in therapeutic management prevents discontinuation without medical assistance and guarantees adequate treatment, as well as its effectiveness.
  • the invention prevents the patient from misusing the medication, ingesting larger amounts than those recommended by the doctor and becoming more susceptible to unwanted side effects and worsening of their clinical condition.
  • the anorectic implant avoids the “peaks and valleys” of oral administration and decreases the amount of medication needed for the therapeutic effect, limiting the side effects.
  • the simplification of dosage and decrease in the frequency of administration also adds economic value to the product and promotes greater adherence to treatment.
  • Another benefit of this invention is the release of the drug, through the implants, directly into the bloodstream, which makes its action much more efficient and avoids the first-pass metabolism of the drug.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente demande de brevet relève du secteur de la santé et consiste en un implant sous-cutané réabsorbable de longue durée à libération prolongée de substance pharmacologiquement active pré-concentrée en polymère pour le traitement de l'obésité. L'implant est inséré par voie sous-cutanée et possède une libération continue du principe actif pendant une période prolongée, garantissant un taux sérique de l'agent pharmaceutique efficace et constant dans le traitement de l'obésité. L'implant peut présenter, dans sa constitution, des particules de l'agent anorexigène dispersées de manière homogène dans une matrice polymère bioérodable et bioabsorbable. L'implant peut posséder une membrane polymère de revêtement et le polymère utilisé pour le revêtement doit être bioabsorbable et permettre le passage du principe actif.
PCT/BR2020/050348 2020-07-16 2020-08-31 Implant sous-cutané réabsorbable de longue durée à libération prolongée de substance pharmacologiquement active pré-concentrée en polymère pour le traitement de l'obésité et procédé WO2022011439A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BR102020014545-2 2020-07-16
BR102020014545-2A BR102020014545A2 (pt) 2020-07-16 2020-07-16 Implante subcutâneo reabsorvível de longa duração com liberação prolongada de substância farmacologicamente ativa pré-concentrada em polímero para tratamento da obesidade e processo

Publications (1)

Publication Number Publication Date
WO2022011439A1 true WO2022011439A1 (fr) 2022-01-20

Family

ID=79555866

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2020/050348 WO2022011439A1 (fr) 2020-07-16 2020-08-31 Implant sous-cutané réabsorbable de longue durée à libération prolongée de substance pharmacologiquement active pré-concentrée en polymère pour le traitement de l'obésité et procédé

Country Status (2)

Country Link
BR (1) BR102020014545A2 (fr)
WO (1) WO2022011439A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102022010454A2 (pt) * 2022-05-27 2023-12-05 Edson Luiz Peracchi Implante subcutâneo reabsorvível de longa duração com liberação prolongada de substância farmacologicamente ativa pré-concentrada em polímero para tratamento adjuvante da epilepsia, dor crônica e ansiedade e processo

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011034A1 (fr) * 1993-10-22 1995-04-27 Keown Wendy J Preparation amaigrissante contenant de l'ephedrine et un sel ou un chelate mineral
WO2007112436A2 (fr) * 2006-03-28 2007-10-04 Gelesis, Inc. Utilisation de materiaux polymeres avec d'autres substances pour des performances ameliorees
WO2008063673A1 (fr) * 2006-11-21 2008-05-29 Dov Pharmaceutical, Inc. Procédés et composition permettant de réguler le poids corporel et l'appétit
WO2009049105A2 (fr) * 2007-10-09 2009-04-16 Gelesis, Inc. Procédés d'induction du rassasiement

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011034A1 (fr) * 1993-10-22 1995-04-27 Keown Wendy J Preparation amaigrissante contenant de l'ephedrine et un sel ou un chelate mineral
WO2007112436A2 (fr) * 2006-03-28 2007-10-04 Gelesis, Inc. Utilisation de materiaux polymeres avec d'autres substances pour des performances ameliorees
WO2008063673A1 (fr) * 2006-11-21 2008-05-29 Dov Pharmaceutical, Inc. Procédés et composition permettant de réguler le poids corporel et l'appétit
WO2009049105A2 (fr) * 2007-10-09 2009-04-16 Gelesis, Inc. Procédés d'induction du rassasiement

Also Published As

Publication number Publication date
BR102020014545A2 (pt) 2022-01-25

Similar Documents

Publication Publication Date Title
Johnson Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function
KR101068603B1 (ko) 지방 조직, 피부 조직, 피부 질환 및 근육 조직의 치료를 위한 제제
JP2023024704A (ja) 絶食条件下でのタシメルテオンの投与
Oertel et al. Late (complicated) Parkinson’s disease
WO2001070154A9 (fr) Dispositif et procede de traitement de l'incontinence urinaire chez les femmes
AU2023202003A1 (en) Melatonin mini-tablets and method of manufacturing the same
Odin et al. Restless legs syndrome
WO2022011439A1 (fr) Implant sous-cutané réabsorbable de longue durée à libération prolongée de substance pharmacologiquement active pré-concentrée en polymère pour le traitement de l'obésité et procédé
JP5106809B2 (ja) ラクトフェリンを含有する医薬組成物ならびに加工食品
US20230255882A1 (en) Long-lasting resorbable subcutaneous implant with sustained release of pre-concentrated pharmacologically active substance in polymer for the treatment of parkinsons disease
CN106619558A (zh) 一种芬戈莫德胃溶型微丸片及其制备方法
KR20210097487A (ko) 후코이단을 포함하는 수면장애 예방, 개선 또는 치료용 조성물
US20240165064A1 (en) Long-lasting resorbable subcutaneous implant with prolonged release of pre-concentrated pharmacologically active substance in polymer for the treatment of hypothyroidism, and method
WO2022120444A1 (fr) Implant sous-cutané réabsorbable de longue durée à libération prolongée de substance pharmacologiquement active pré-concentrée en polymère pour le traitement de la dépendance à la nicotine et procédé
BR102021014927A2 (pt) Implante subcutâneo reabsorvível de longa duração com liberação prolongada de substância farmacologicamente ativa pré-concentrada em polímero para tratamento do hipotireoidismo e processo
WO2022160022A1 (fr) Implant sous-cutané réabsorbable de longue durée à libération prolongée de substance pharmacologiquement active pré-concentrée en polymère pour le traitement du diabète de type 2 et procédé
WO2021237321A1 (fr) Implant sous-cutané réabsorbable de longue durée à libération prolongée de substance pharmacologiquement active pré-concentrée en polymère pour le traitement de l'insuffisance surrénalienne chronique ou hypocortisolisme
WO2023225728A1 (fr) Implant sous-cutané réabsorbable de longue durée à libération prolongée de substance pharmacologiquement active pré-concentrée en polymère pour le traitement complémentaire de l'épilepsie, de douleurs chroniques et de l'anxiété, et méthode
BR102021020738A2 (pt) Implante subcutâneo reabsorvível de longa duração com liberação prolongada de substância farmacologicamente ativa pré-concentrada em polímero para a manutenção de níveis adequados de dhea e dhea-s e processo
WO2021237322A1 (fr) Implant sous-cutané réabsorbable de longue durée à libération prolongée de substance pharmacologiquement active pré-concentrée en polymère pour le traitement de la dysfonction érectile et de l'hyperplasie bénigne de la prostate
BR102021022749A2 (pt) Implante subcutâneo reabsorvível de longa duração com liberação prolongada de substância farmacologicamente ativa pré-concentrada em polímero para a insulinoterapia no diabetes mellitus e processo
Zesiewicz et al. Medical treatment of motor and nonmotor features of Parkinson's disease
US20160367559A1 (en) Time Released Caffeine
CN113271929A (zh) 用于帮助睡眠的组合物及方法
WO2023178250A1 (fr) Traitement de la sclérose tubéreuse avec du mirdametinib

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20945197

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20945197

Country of ref document: EP

Kind code of ref document: A1